Our findings revealed PDE4D might act as a critical mediator between NAFLD and associated kidney injury and indicated PDE4 inhibitor roflumilast as a potential therapeutic strategy for NAFLD-associated CKD. Here, PDE4A is linked to metabolic dysfunction-associated steatotic liver disease.